BHVN
Price
$15.61
Change
+$0.45 (+2.97%)
Updated
Nov 3 closing price
Capitalization
2.36B
124 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$6.28
Change
+$0.28 (+4.67%)
Updated
Nov 3 closing price
Capitalization
673.37M
132 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BHVN vs SLDB

BHVN vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BHVN vs. SLDB commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a StrongBuy and SLDB is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BHVN with price predictions
Nov 03, 2026

BHVN in upward trend: price rose above 50-day moving average on October 22, 2026

BHVN moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BHVN as a result. In 86 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for BHVN just turned positive on October 21, 2026. Looking at past instances where BHVN's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

The 10-day moving average for BHVN crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +7.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where BHVN advanced for three days, in 200 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The 10-day RSI Indicator for BHVN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

BHVN broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BHVN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. BHVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BHVN's P/B Ratio (192.914) is very high in comparison to the industry average of (3.051). P/E Ratio (-3.431) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SLDB with price predictions
Nov 03, 2026

SLDB in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026

SLDB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 42 cases where SLDB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Oscillator exited the oversold zone, 33 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.

Following a +11.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 203 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where SLDB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLDB as a result. In 57 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for SLDB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.800) is normal, around the industry mean (3.051). P/E Ratio (-3.323) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
BHVN vs SLDB: Fundamental Ratings
BHVN
SLDB
OUTLOOK RATING
1..100
4369
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3863
P/E GROWTH RATING
1..100
5020
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (32) in the Biotechnology industry is significantly better than the same rating for BHVN (98) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew significantly faster than BHVN’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew similarly to BHVN’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as BHVN (100) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew similarly to BHVN’s over the last 12 months.

BHVN's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as SLDB (63) in the Biotechnology industry. This means that BHVN’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (20) in the Biotechnology industry is in the same range as BHVN (50) in the Pharmaceuticals Major industry. This means that SLDB’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNSLDB
RSI
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (BHVN: $15.61 vs. SLDB: $6.28)
Brand notoriety: BHVN and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 62% vs. SLDB: 49%
Market capitalization -- BHVN: $2.36B vs. SLDB: $673.37M
BHVN [@Biotechnology] is valued at $2.36B. SLDB’s [@Biotechnology] market capitalization is $673.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than BHVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • BHVN’s TA Score: 5 bullish, 5 bearish.
  • SLDB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BHVN and SLDB are a good buy in the short-term.

Price Growth

BHVN (@Biotechnology) experienced а +2.09% price change this week, while SLDB (@Biotechnology) price change was +1.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.

Reported Earning Dates

BHVN is expected to report earnings on Mar 08, 2027.

SLDB is expected to report earnings on Mar 16, 2027.

Industries' Descriptions

@Biotechnology (-2.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BHVN
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PJFM65.640.83
+1.27%
PGIM Jennison Focused Mid-Cap ETF (PJFM)
GEMG3.52N/A
N/A
Leverage Shares 2X Long GEMI Daily ETF (GEMG)
HFSI33.78-0.04
-0.10%
Hartford Strategic Income ETF (HFSI)
KBWY16.54-0.16
-0.96%
Invesco KBW Premium Yield Equity REIT ETF (KBWY)
TSLR19.24-0.55
-2.78%
GraniteShares 2x Long TSLA Daily ETF (TSLR)